tbuckley/cabot-search huggingface dataset:
PWE-144 Small Bowel Capsule Endoscopy In Patients With Cirrhosis: The Edinburgh Experience: Abstract PWE-144 Table 1
Authors: KJ Dabos, A Koulaouzidis, PC Hayes, JN Plevris
Journal: Gut (2014)

<h3>Introduction</h3> Portal hypertensive enteropathy (PHE) remains difficult to diagnose in patients with cirrhosis and portal hypertension. Limited test choices exist for the inspection of the small bowel in these patients. Small bowel capsule endoscopy (SBCE) would be ideal in this situation but it is rarely performed.<sup>1–3</sup> <h3>Aim</h3> We aimed to determine the prevalence of PHE using SBCE in a cirrhotic patient population from our centre. <h3>Methods</h3> This was a retrospective study using the SBCE data base of our unit. We searched through 1,477 patients that had SBCE between 2005 and 2013. Patients with cirrhosis who underwent SBCE were identified, data retrieved and abstracted. The Fischer’s exact or the chi-square tests were used to compare between groups. A two-tailed <i>P</i> value of &lt;0.05 was considered statistically significant. <h3>Results</h3> We identified 53 patients with cirrhosis who underwent SCBE. We used PillCam<sup>®</sup>SB (Given<sup>®</sup>Imaging Ltd, Israel) system on 36 patients and the MiroCam<sup>®</sup> capsule (IntroMedic Co, Korea) on 17 patients. Thirty patients were referred for iron deficiency anaemia, 15 for obscure gastrointestinal bleeding, and 4 for other indications. Four data sets were not available for review at the time of the study, leaving 49 patients to be reviewed. Mean age was 61.19 ± 14.54 years (M/F=27/22). Table 1 shows the aetiologies of liver disease in these patients. Six SBCE examinations were incomplete. Thirty three patients had evidence of portal hypertensive gastropathy (PHG) and 17 patients had evidence of oesophageal varices. In total, 29 patients had SCBE evidence of PHE (67%). 28/29 (96.5%) of patients with PHE had also evidence of PHG. 13/17 (76.4%) patients with oesophageal varices had also evidence of PHE. Our mean follow up was 58.0 ± 13.7 months. Twenty patients died during the follow up period. There was no correlation between the presence of PHE and aetiology of liver disease (P<i> = 0</i>.4261) or subsequent death (P= 0.2145). <h3>Conclusion</h3> The prevalence of PHE in our study was 67%. SBCE is a useful tool in evaluating PHE in cirrhotic patients irrespective of aetiology. <h3>References</h3> Rondonotti E, <i>et al</i>. Capsule endoscopy in portal hypertension. <i>Clin Liver Dis</i> 2010;14:209–20. Krystallis C, <i>et al</i>. Update of endoscopy in liver disease: more than just treating varices. <i>World J Gastroenterol</i> 2012;18:401–11 Sidhu R, <i>et al</i>. Does small bowel capsule endoscopy alter management in patients with liver disease? <i>Scand J Gastroenterol</i> 2011;46:123–4 <h3>Disclosure of Interest</h3> None Declared.
Abstract CT130: Intravenous chemotherapy plus intraperitoneal perfusion chemotherapy for gastric cancer: A systematic review and meta-analysis
Authors: Sheng Yang, Rui Feng, Zhangchi Pan, Tao Jiang, Qian Xu, Qiang Chen
Journal: Cancer Research (2015)

Abstract Purpose: This a review of randomized controlled trials (RCTs) of intravenous (IV) with or without intraperitoneal (IP) chemotherapy in patients with gastric cancer to determine the impact on effect and safety. Methods: Databases, including Medline, Embase, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, Current Controlled Trials, and CINAHL were electronically searched for RCTs up to June 2013, and relevant references of the included articles were also manually searched. Two authors independently searched articles, extracted data, and assessed the quality of included studies. Meta-analyses were performed on the included data, for the outcomes survival rate, metastasis rate and adverse events. The Grading of Recommendations Assessment, Development and Evaluation System was used to rate the level of evidence. Results: Five RCTs involving 1072 patients were included. Overall, a significant improvement in overall survival rate [relative risk (RR) = 1.21, 95% confidence interval (95% CI) 1.13 to 1.29, P&amp;lt;0.01], one-year survival rate (RR = 1.10, 95% CI 1.04 to1.17, P = 0.005), three-year survival rate (RR = 1.22, 95% CI 1.11 to1.35, P = 0.001), and five-year survival rate (RR = 1.42, 95% CI 1.12 to 1.80, P = 0.004) were associated with IV plus IP chemotherapy. Meta-analysis demonstrated that metastasis rate can be effectively decreased (RR = 0.35, 95% CI 0.25 to 0.50, P&amp;lt;0.01) but incidence of adverse events were increased using IV plus IP chemotherapy. Conclusion: IV plus IP chemotherapy in patients with gastric cancer is associated with improved overall survival and prevented distant or peritoneal metastasis. However, increased risk of neutropenia, peripheral edema and neuropathy are also demonstrated. Citation Format: Sheng Yang, Rui Feng, Zhangchi Pan, Tao Jiang, Qian Xu, Qiang Chen. Intravenous chemotherapy plus intraperitoneal perfusion chemotherapy for gastric cancer: A systematic review and meta-analysis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT130. doi:10.1158/1538-7445.AM2015-CT130
SAT0191 Disease Progression in SSC-Overlap Syndromes is Significantly Different from Limited and Diffuse Cutaneous SSC
Authors: P. Moinzadeh, N. Hunzelmann, T. Krieg, N. Blank, F. Gerhard, E. Genth, K. Graefenstein, I. Koetter, A. Kreuter, I. Melchers, C. Pfeiffer, U. Müller-Ladner, G. Riemekasten, M. Sardy, C. Seitz, C. Sunderkoetter, G. Wozel
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Overlap syndromes are a very heterogeneous and remarkable group of patients, who present at least two connective tissue diseases (CTDs) at the same time, usually with a specific autoantibody status. Currently it is still debated, whether SSc patients showing signs of overlaps to other connective tissue diseases should be regarded as a specific disease subset. <h3>Objectives</h3> To determine whether patients, classified as overlap syndromes, show a disease course different from patients with limited (lcSSc) and diffuse cutaneous SSc (dcSSc). <h3>Methods</h3> We here present the data of a prospective study, involving well-defined 3323 patients, registered (with yearly follow-up informations) in a database of the German network for systemic sclerosis (DNSS). The following statistical methods were used: Kaplan-Meier analysis, cox regression, logistic regression, McNemar test as well as א<sup>2</sup>test/Fisher's exact test. <h3>Results</h3> Among 3323 registered patients, 10% (325/3240) were diagnosed as SSc-overlap syndrome. Of these, 82.5% (268/325) were female with a mean age of 49, 2 ± 1.2 years. Significantly more of them developed musculoskeletal involvement, compared to lcSSc and dcSSc patients (37.8 %, 47.8%; p&lt;0.0001) and carried significantly more often other antibodies (71.1%; p&lt;0.0001), which were separated into U1RNP- (22.7%), Ro- (16.8%), PmScl- (11.5%) antibodies, followed by 10.8% with rheumatoid factors, 7.5% with La-, 5.8% with dsDNA- and 2.8% with Jo-1- and 2.6% with Ku-antibodies. The Kaplan-Meier analysis of the onset of organ involvement revealed a clear inclined position of overlap patients between patients suffering from lcSSc and dcSSc, especially regarding lung fibrosis and heart involvement. Patients suffering from PAH, oesophagus involvement and kidney involvement, overlap and lcSSc patients showed nearly similar curve progression (log rank&lt;0.0001). Furthermore musculoskeletal involvement was significantly more frequent and more progressive in patients with overlap disease, followed by patients with dcSSc and lcSSc (log rank&lt;0.0001). <h3>Conclusions</h3> These data support the current concept, that SSc-overlap syndromes should be regarded as a separate SSc subset, distinct from lcSSc and dcSSc, due to a different course of the disease, different proportional distribution of specific autoantibodies and skin/organ involvement. <h3>Disclosure of Interest</h3> None Declared
Concamitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient
Authors: G Martinelli, M Amabile, C Terragna, N Testoni, E Ottaviani, V Montefusco, A de Vivo, M Baccarani, P Ricci, G Saglio, S Tura
Journal: Leukemia (1999)
RESECCIÓN ENDOSCÓPICA MUCOSA DE NEOPLASIAS SUPERFICIALES ALTAS: ESTUDIO DE EFICACIA Y SEGURIDAD EN 147 RESECCIONES CONSECUTIVAS
Authors: E Albéniz, A Pueyo, J Eguaras, A Ciáurriz, M Fraile, D Ruiz-Clavijo, R Iglesias, S Rubio, S Oquiñena, C Jiménez
Journal: Endoscopy (2011)

Introducción: la resección endoscópica mucosa (REM) o mucosectomía se considera una técnica aceptada en el tratamiento de lesiones neoplásicas superficiales, constituyendo una alternativa al tratamiento quirúrgico convencional.
Abstract P1-12-01: Preoperative Endocrine Therapy with Tamoxifen and Goserelin Acetate for Hormone Receptor-Positive Premenopausal Patients
Authors: D Shimizu, T Ishikawa, A Yamada, M Tanaabe, T Chishima, T Sasaki, I. Endo
Journal: Cancer Research (2010)

Abstract Background: Clinical trials have consistently shown that the response rates of hormone receptor-positive breast cancer patients to neoadjuvant chemotherapy are low. Preoperative endocrine therapy has therefore become a logical alternative for such patients. Several researchers have reported favorable response rates in postmenopausal women. However, the effectiveness of preoperative endocrine therapy for premenopausal women remains unknown. The aim of this study was to evaluate the potential benefits of preoperative endocrine therapy for premenopausal women. Materials and methods: Forty premenopausal patients with operable estrogen receptor (ER)-positive breast cancer were consecutively treated with neoadjuvant therapy with tamoxifen and Goserelin acetate for 3 months. The patients eligible for this study included clinically node-negative patients with tumors that were less than 2 cm in diameter and negative for human epidermal growth factor receptor 2 (HER2). All the patients were clinically evaluated using ultrasonograpy before and after the endocrine therapy. Further, core-needle biopsy specimens obtained before administration of the endocrine therapy and surgical specimens were pathologically evaluated for ER, progesterone receptor (PgR), HER2, p53, and Ki67 expressions. This study was approved by our institutional IRB. Results: The patients included in this study were 30-52 years old (median age, 43 years). The size of the tumor was 0.9-2.0 cm (median, 1.5 cm). The clinical response rate was 20% (8/40) and disease progression was not observed. In the case of 39 of the 40 patients, grade 0 or grade 1 pathological response was observed. Clinical responses were not correlated with pathological responses. The ER expression level before the endocrine therapy differed from that after the therapy in the case of 8% (2/40) of the patients (increased in 4% and decreased in 4%). Further, PgR expression was altered in the case of 50% (20/40) of the patients (increased in 8% and decreased in 42%). Moreover, Ki67 expression was decreased in 90% (36/40) of the patients after the endocrine therapy. Conclusions: This is the first report on neoadjuvant endocrine therapy for premenopausal patients. Disease progression 3 months after the endocrine therapy was not observed. Because the expressions of Ki67 and PgR decreased, these molecules might be candidate markers of endocrine responsiveness in premenopausal patients. To confirm this assumption, further evaluations involving tumors of a larger size, longer observational period, and more number of eligible patients are planned to be conducted. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-12-01.
Abstract 1322: Molecular mechanisms of high glucose-induced toxicity in human breast adenocarcinoma (Mcf-7) cells
Authors: Clement G. Yedjou, Christine K. Tchounwou, Paul B. Tchounwou
Journal: Cancer Research (2011)

Abstract Glucose is a simple sugar that your body relies on it to produce energy. It has been shown that high glucose is related to many long-term health problems including the kidneys, nerves, eyes and vision, risk of heart disease and stroke, erectile dysfunction in men and pregnancy complications in women. Epidemiological data have suggested an increased cancer rates in diabetic patients, for which the underlying mechanism is poorly understood. Hence, the aim of the present investigation was to evaluate the cell viability of human breast adenocarcinoma (MCF-7) cells exposed to different doses (0, 5, 10, 20, 40, 80 mg/mL) of D-glucose by the means of trypan blue exclusion test and MTT assay, respectively. The degree of DNA damage and early stage apoptosis were also tested by the means of alkaline single cell gel electrophoresis (Comet) assay, and flow cytometric analysis using Annexin V FITC/PI. The results of MTT assay indicated that low dose (5 mg/mL) of D-glucose slightly increase cell viability upon 2 h of exposure. On the other hand, high doses (10-80 mg/mL) of D-glucose significantly reduce the viability of MCF-7 cells in a dose and time-dependent manner. Similar trend was obtained with the trypan blue exclusion test. Data obtained from the comet assay indicated that D-glucose causes DNA damage in MCF-7 cells in a dose-dependent manner. The flow cytometric assessment (Annexin V FITC/PI) showed a strong dose-response relationship between high glucose exposure and annexin V positive cells undergoing early stage apoptosis in MCF-7 cells. Based on these direct in vitro findings, our study shows clear evidence that elevated level of D-glucose induced cytotoxic and genotoxic effects, and apoptosis in MCF-7 cells. This finding provides evidence that elevated level of glucose may be is associated with diabetic complications in vascular endothelium of the female breasts. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1322. doi:10.1158/1538-7445.AM2011-1322
Pancreatic Angiography, with Application of Subselective Angiography of the Celiac or Superior Mesenteric Artery to the Diagnosis of Carcinoma of the Pancreas
Authors: Robert E. Paul, Harry H. Miller, Paul C. Kahn, Allan D. Callow, Ted L. Edwards, James F. Patterson
Journal: New England Journal of Medicine (1965)

THE diagnosis of pancreatic neoplasms is difficult because of the inaccessibility of the organ to the usual means of examination. Conventional methods of diagnostic, radiography are helpful in only a few cases, usually restricted to those with large tumors that impinge upon or distort adjacent viscera. The x-ray technic of angiographic visualization of blood vessels bordering and situated within the pancreas offers the means of establishing the presence of a tumor of this organ. Angiographic demonstration of the pancreatic vasculature by aortography alone is of no significant value because the finer pancreatic vessels are poorly opacified and obscured by the . . .
AB0663 Comparative study of personality fibromyalgia and other rheumatic diseases. a preliminary study
Authors: V. Martaille, E. Bucourt, R. Courtois, D. Mulleman, P. Goupille
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> It is popularly believed thatpatients with fibromyalgia display a neurotic personality. Our hypothesis was that patients with fibromyalgia had higher scores of neurocitism and introversion than in other rheumatic diseases. <h3>Objectives</h3> To compare the personality between patients with fibromyalgia and patients with other rheumatic diseases. The hypothesis of apersonality type of FM patients has already been mentioned in literature, as evidenced by two literature reviews of Auquier <i>et al.</i> (1)and Fieta <i>et al.</i>(2)which show conflicting results. We compared the five major personality traits in patients with fibromyalgia andin patients followed for other rheumatic diseases, including Rheumatoid Arthritis (RA), Gougerot Sjögren syndrome (SS), and Spondyloarthritis (SpA). <h3>Methods</h3> The Big Five Inventory (BFI) questionnaire (3) was used to assess and compare the five major personality dimensions of patients with fibromyalgia, RA, SpA or SS. Patients were included between June 2010 and January 2011. They had to be women, without any concomitant chronic disease or malignancies, with disease duration less than 10 years. Validated diseases criteria were used to select patients. <h3>Results</h3> Sixty-fourpatients filled the questionnaire. These patients were followed for fibromyalgia (n = 15), RA (n = 16), SpA (n = 18), or SS (n = 15). The patients with fibromyalgia group had a higher score of agreeableness than other patients groups (p= 0,006). There was no significant difference in the neuroticismscore (p = 0.451) between patients with fibromyalgia and the other studied groups. <h3>Conclusions</h3> Neurocitism do not seem to be higher in fibromyalgia group than in other rheumatic diseases. <h3>References</h3> Auquier L, Bontoux D, Löo H, Godeau P, Menkès C-J, Paolaggi J-B, et al. [Fibromyalgia]. Rev Med Interne. 2008 Feb;29(2):161–8. Fietta P, Manganelli P. Fibromyalgia and psychiatric disorders. Acta Biomed. 2007 Aug;78(2):88–95. Plaisant O, Courtois R, Réveillère C, Mendelsohn GA, John OP. Validation par analyse factorielle du Big Five Inventory français (BFI-Fr). Analyse convergente avec le NEO-PI-R. Annales Médico-psychologiques, revue psychiatrique. 2010 Mar;168(2):97–106. <h3>Acknowledgements</h3> The authors thank Dr Isabelle Vannier for recruiting patients with fibromyalgia and Dr Brigitte Huttenberger, for recruiting patients with Sjögren syndrome. <h3>Disclosure of Interest</h3> None Declared
Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration
Authors: Lisa Marshall, Timothy Hickling, David Bill, Ehab Mahgoub
Journal: Annals of the Rheumatic Diseases (2016)

In their 2015 publication, Emery et al 1 reported findings of a phase III, randomised, double-blind study comparing the investigational etanercept biosimilar SB4 (Samsung Bioepis, Incheon, Korea) with the innovator etanercept in patients who have moderate-to-severe rheumatoid arthritis (RA) despite methotrexate treatment. Although the authors reported equivalent clinical efficacy between the SB4 and reference product, they found a significantly lower incidence of antidrug antibodies (ADAs) against SB4 than against etanercept, that is, 2 (0.7%) patients in the SB4 group and 39 (13.1%) patients in the etanercept group were ADA positive by week 24 (p<0.001). We acknowledge the two recently published Letters to the Editor of the Annals of the Rheumatic Diseases by Moots et al 2 and a response by Emery et al ,3 in which important aspects of these immunogenicity results were discussed, and would also like to offer an additional consideration.

The etanercept immunogenicity findings reported in the original manuscript1 warrant closer inspection, as they are inconsistent with those reported in …
Abstract 779: ARF activation is responsible for the tumor-suppressing function of p53 in basal cell carcinomas (BCCs) in Ptch1+/- mice.
Authors: Grace Y. Wang, Carla Wood, Joy Wang, Lynn Wang, Eileen Libove, Ervin Epstein
Journal: Cancer Research (2013)

Abstract Basal cell carcinomas (BCCs) are the most common cancer among people of European ancestry. Aberrant activation of hedgehog (HH) signaling plays a pivotal role in BCC carcinogenesis. Besides mutations in genes encoding HH pathway components, mutations in the p53 gene frequently are found in human BCCs. Consistently, our previous studies have found that the loss of p53 can dramatically accelerate BCC formation in ionizing radiation (IR)-treated Ptch1+/- mice. It remains elusive how p53 is activated in BCC development. DNA damage response (DDR) and oncogenic induced stress (OIS) are two essentially independent pathways leading to p53 activation although limited evidence suggests crosstalk between these pathways. In response to OIS, ARF is activated and leads to p53 activation, functioning as a tumor suppressor, in many cancers. However, the loss of ARF, unlike loss of p53, failed to affect the development of medulloblastoma in Ptch1+/- mice (Wetmore C., et al, 2001). In the present study, we investigated whether ARF affects BCC development in the same mice. To address this, we bred ARFGFP/GFP mice, in which ARF function is disabled and GFP is expressed under the control of the endogenous ARF promoter, with our Ptch1+/- mice to generate Ptch1+/- ARFGFP/GFP (designated as ARF mice) for comparison with Ptch1+/- K14CreER2 p53fl/fl (PF) mice. Following our standard protocol of tamoxifen injection at age 7.5 weeks to delete p53 specifically in K14-expressing keratinocytes (for PF mice) and treating both ARF and PF mice with ionizing radiation at age 8 weeks, we compared BCC development between the above 2 lines. We find that at age 5 months, ARF mice formed numbers of microscopic BCCs comparable to those in PF mice though the latter exhibited greater mouse-to-mouse variation. More importantly, both mouse lines developed initial visible BCCs at age 5 to 7 months, which is dramatically earlier than the age 9 to 18 months for the Ptch1+/- mice (ARF+/+ and p53+/+). In addition, ARFGFP/GFP mice responded to IR-induced DNA damage in a pattern essentially similar to ARF+/+ mice, indicating an intact DDR pathway as reported in the literature. In conclusion, our data demonstrate that ARF is involved in BCC carcinogenesis as a tumor suppressor, probably playing the major, perhaps the exclusive, role in activating p53 in this process. Citation Format: Grace Y. Wang, Carla Wood, Joy Wang, Lynn Wang, Eileen Libove, Ervin Epstein. ARF activation is responsible for the tumor-suppressing function of p53 in basal cell carcinomas (BCCs) in Ptch1+/- mice. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 779. doi:10.1158/1538-7445.AM2013-779
A Randomized Trial of Three Maintenance Regimens Given after Three Months of Induction Therapy with Zidovudine, Lamivudine, and Indinavir in Previously Untreated HIV-1–Infected Patients
Authors: Gilles Pialoux, François Raffi, Françoise Brun-Vezinet, Vincent Meiffrédy, Philippe Flandre, Jean-Albert Gastaut, Pierre Dellamonica, Patrick Yeni, Jean-François Delfraissy, Jean-Pierre Aboulker
Journal: New England Journal of Medicine (1998)

The long-term effectiveness of potent three-drug antiretroviral regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection is limited by problems related to compliance and tolerability. We investigated whether two-drug maintenance therapy would suppress viral replication after a three-month period of aggressive triple-drug induction therapy.
PSYCHOLOGICAL EFFECTS OF CORTISONE IN ACUTE CATATONIC EXCITEMENT
Authors: WILLIAM S. WIEDORN
Journal: American Journal of Psychiatry (1955)

A patient who experienced an acute schizophrenic episode during an otherwise uneventful recovery following gun-shot wounds and surgery was treated with large amounts of cortisone. During cortisone therapy changes were encountered in her behavior, symbolic productions, and level of integration. In this patient the period of administration of large amounts of cortisone coincided with reversal of the downhill course and with development of interpersonal contact with subsequent gains in environmental relationships.